Past, imminent and future human medical countermeasures for anthrax
- PMID: 16907809
- DOI: 10.1111/j.1365-2672.2006.03112.x
Past, imminent and future human medical countermeasures for anthrax
Abstract
Aim: Anthrax is caused by the bacterium Bacillus anthracis. Although primarily a disease of animals, it can also infect man, sometimes with fatal consequences. As a result of concerns over the illicit use of this organism, considerable effort is focussed on the development of therapies capable of conferring protection against anthrax. This brief review will describe the efforts being made to address these issues.
Methods and results: A review of the literature and the proceedings of the sixth international conference on anthrax, held in Santa Fe, USA in 2005 shows intense activity, but there has been as yet no real progress. While effective antibiotics, antitoxins and vaccines are available, concerns over their toxicity and the emergence of resistant strains have driven the development of second-generation products. The principal target for vaccine development is Protective Antigen (PA), the nontoxic cell-binding component of anthrax lethal toxin. While the recombinant products currently undergoing human clinical trials will offer considerable advantages in terms of reduced side effects and ease of production, they would still require multiple, needle-based dosing, and the inclusion of the adjuvant alum makes them expensive to administer and stockpile. To address these issues, researchers are developing vaccine formulations, which stimulate rapid protection following needle-free injection (nasal, oral or transcutaneous), and are stable at room temperature to facilitate stockpiling and mass vaccination programs.
Conclusions: An array of medical countermeasures targeting B. anthracis will become available over the next 5-10 years.
Significance and impact of the study: The huge investment of research dollars is expected to dramatically expand the knowledge base. A better understanding of basic issues, such as survival in nature and pathogenesis in humans, will facilitate the development of new modalities to eliminate the threat posed by this organism.
Similar articles
-
Is new always better than old?: The development of human vaccines for anthrax.Hum Vaccin. 2009 Dec;5(12):806-16. doi: 10.4161/hv.9777. Epub 2009 Dec 9. Hum Vaccin. 2009. PMID: 19786839 Review.
-
Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.Expert Rev Anti Infect Ther. 2009 Mar;7(2):219-36. doi: 10.1586/14787210.7.2.219. Expert Rev Anti Infect Ther. 2009. PMID: 19254170 Review.
-
Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.Expert Rev Anti Infect Ther. 2007 Aug;5(4):665-84. doi: 10.1586/14787210.5.4.665. Expert Rev Anti Infect Ther. 2007. PMID: 17678429 Review.
-
Molecular basis for improved anthrax vaccines.Adv Drug Deliv Rev. 2005 Jun 17;57(9):1266-92. doi: 10.1016/j.addr.2005.01.028. Epub 2005 Apr 21. Adv Drug Deliv Rev. 2005. PMID: 15935874 Review.
-
Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.Vaccine. 2005 Dec 1;23(48-49):5688-97. doi: 10.1016/j.vaccine.2004.11.077. Epub 2005 Feb 5. Vaccine. 2005. PMID: 16039760
Cited by
-
Soluble Expression and Characterization of Biologically Active Bacillus anthracis Protective Antigen in Escherichia coli.Mol Biol Int. 2016;2016:4732791. doi: 10.1155/2016/4732791. Epub 2016 Feb 7. Mol Biol Int. 2016. PMID: 26966576 Free PMC article.
-
Antibodies against anthrax: mechanisms of action and clinical applications.Toxins (Basel). 2011 Nov;3(11):1433-52. doi: 10.3390/toxins3111433. Epub 2011 Nov 16. Toxins (Basel). 2011. PMID: 22174979 Free PMC article. Review.
-
Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment.Comp Med. 2010 Dec;60(6):461-8. Comp Med. 2010. PMID: 21262133 Free PMC article.
-
Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor.PLoS One. 2013 May 31;8(5):e65855. doi: 10.1371/journal.pone.0065855. Print 2013. PLoS One. 2013. PMID: 23741517 Free PMC article.
-
Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.Vaccine. 2010 Oct 4;28(42):6901-14. doi: 10.1016/j.vaccine.2010.08.006. Epub 2010 Aug 17. Vaccine. 2010. PMID: 20723629 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous